NASDAQ:TECX Tectonic Therapeutic (TECX) Stock Price, News & Analysis $22.41 -0.70 (-3.03%) Closing price 04:00 PM EasternExtended Trading$22.36 -0.05 (-0.25%) As of 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Tectonic Therapeutic Stock (NASDAQ:TECX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tectonic Therapeutic alerts:Sign Up Key Stats Today's Range$21.83▼$23.2750-Day Range$22.54▼$37.7152-Week Range$14.60▼$39.53Volume200,934 shsAverage Volume264,538 shsMarket Capitalization$438.09 millionP/E RatioN/ADividend YieldN/APrice Target$77.80Consensus RatingModerate Buy Company Overview Tectonic Therapeutic, Inc. (NASDAQ: TECX) is a clinical-stage biotechnology company developing biologic medicines that target G protein-coupled receptors (GPCRs). These receptors play important roles in numerous biological processes and are established targets for a range of therapeutic treatments, but many remain difficult to address with conventional drug-discovery approaches. The company uses its proprietary GEODe platform to identify and develop antibodies and other biologic molecules designed to modulate GPCR activity. Its research and development efforts are focused on creating therapies for serious diseases in areas where current treatment options may be limited. Tectonic’s lead program, TX45, is an engineered relaxin-based therapeutic intended to activate the RXFP1 receptor. The program has been investigated for potential treatment of pulmonary arterial hypertension and other cardiovascular conditions. Tectonic Therapeutic is based in the United States and focuses primarily on advancing its internal discovery and clinical development pipeline.AI Generated. May Contain Errors. Read More Tectonic Therapeutic Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreTECX MarketRank™: Tectonic Therapeutic scored higher than 49% of companies evaluated by MarketBeat, and ranked 509th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingTectonic Therapeutic has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 2 strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTectonic Therapeutic has a consensus price target of $77.80, representing about 235.1% upside from its current price of $23.22.Amount of Analyst CoverageTectonic Therapeutic has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tectonic Therapeutic's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tectonic Therapeutic are expected to decrease in the coming year, from ($5.27) to ($5.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tectonic Therapeutic is -5.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tectonic Therapeutic is -5.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTectonic Therapeutic has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tectonic Therapeutic's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.85% of the float of Tectonic Therapeutic has been sold short.Short Interest Ratio / Days to CoverTectonic Therapeutic has a short interest ratio ("days to cover") of 13.01, which indicates bearish sentiment.Change versus previous monthShort interest in Tectonic Therapeutic has recently increased by 14.22%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTectonic Therapeutic does not currently pay a dividend.Dividend GrowthTectonic Therapeutic does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.31 News SentimentTectonic Therapeutic has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Tectonic Therapeutic this week, compared to 1 article on an average week. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tectonic Therapeutic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,425.00 in company stock.Percentage Held by Insiders39.80% of the stock of Tectonic Therapeutic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.63% of the stock of Tectonic Therapeutic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tectonic Therapeutic's insider trading history. Receive TECX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tectonic Therapeutic and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TECX Stock News HeadlinesTectonic Therapeutic (NASDAQ:TECX) Insider Peter Mcnamara Sells 536 Shares of StockOctober 3 at 6:22 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Solid Biosciences (SLDB)October 1, 2026 | theglobeandmail.comThis list won't be up much longerBill Poulos and his team rebuild their Top 10 Stocks to Buy This Quarter report from scratch every quarter, pulling the old list down the moment a new one goes up. This quarter's edition is still available, but once the next list is published, it disappears for good. Normally priced at 29.97 dollars, it's currently free to download.October 6 at 1:00 AM | Profits Run (Ad)Tectonic Therapeutic Says TX2100 Phase 1a Trial Met Primary ObjectivesSeptember 29, 2026 | finance.yahoo.comTectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)September 29, 2026 | globenewswire.comTectonic Therapeutic, Inc. (NASDAQ:TECX) Stock Has Average Price Target of $77.25 According to BrokeragesSeptember 26, 2026 | americanbankingnews.comTectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare ConferenceSeptember 3, 2026 | globenewswire.comTectonic Therapeutic: Competitor Data Strengthens The TX45 Bull CaseSeptember 2, 2026 | seekingalpha.comSee More Headlines TECX Stock Analysis - Frequently Asked Questions How have TECX shares performed this year? Tectonic Therapeutic's stock was trading at $20.86 at the beginning of the year. Since then, TECX shares have increased by 11.3% and is now trading at $23.2150. How were Tectonic Therapeutic's earnings last quarter? Tectonic Therapeutic, Inc. (NASDAQ:TECX) issued its quarterly earnings results on Thursday, August, 6th. The company reported ($1.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.35) by $0.17. When did Tectonic Therapeutic IPO? Tectonic Therapeutic (TECX) raised $89 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,247,958 shares at a price of $16.00-$18.00 per share. How do I buy shares of Tectonic Therapeutic? Shares of TECX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tectonic Therapeutic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tectonic Therapeutic investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/06/2026Today10/06/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 13 days, TECX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TECX Previous SymbolNASDAQ:TECX CIK1681087 Webwww.tectonictx.com Phone617-914-8420FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Tectonic Therapeutic$77.80 High Price Target$93.00 Low Price Target$60.00 Potential Upside/Downside+247.2%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($4.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.15 million Net MarginsN/A Pretax MarginN/A Return on Equity-35.26% Return on Assets-33.59% Debt Debt-to-Equity RatioN/A Current Ratio22.29 Quick Ratio22.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.43 per share Price / Book1.67Miscellaneous Outstanding Shares19,549,000Free Float11,768,000Market Cap$438.09 million OptionableN/A Beta3.28 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:TECX) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredThis list won't be up much longerBill Poulos and his team rebuild their Top 10 Stocks to Buy This Quarter report from scratch every quarter, pu...Profits Run | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tectonic Therapeutic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tectonic Therapeutic With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TECX Stock Alerts